ArticleCureus2025
A Retrospective Study of Best Supportive Care as Initial Treatment for Oral Squamous Cell Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Patients with oral squamous cell carcinoma (OSCC) may choose best supportive care (BSC) as initial treatment over active treatment for several reasons. However, no previous reports have compared the clinical characteristics of OSCC patients opting for BSC as initial treatment with those receiving standard treatment. This study retrospectively analyzed these differences to identify the factors influencing this decision. Materials and methods This retrospective study was conducted at Niigata University Medical and Dental Hospital, using medical records within January 2018-December 2022 (follow-up until June 2023). Among 135 patients with primary OSCC, received BSC (BSC group) and underwent standard treatment according to the disease stage (non-BSC group). Data included demographic and tumor characteristics, Eastern Cooperative Oncology Group Performance Status (ECOG-PS), underlying diseases, neutrophil-lymphocyte ratio (NLR), albumin levels, living situation (with family, in a care facility, or alone), rationale for BSC selection (untreatable due to poor general condition or no desire for treatment), overall survival (OS) rate, and disease-specific survival (DSS) rate. Age, NLR, and albumin levels were assessed using Student's t-test. Stage classification, ECOG-PS, and living situation were analyzed using the chi-square test. OS and DDS were calculated using the Kaplan-Meier method and compared using the log-rank test. Multiple logistic regression analysis identified factors associated with BSC. Results The BSC group included 11 males and 13 females (mean age: 84 years; range: 47-92). The non-BSC group included 67 males and 44 females (mean age: 67.4 years; range: 31-89). Female predominance was higher in the BSC group (male-female ratio: 1:1.2) than in the non-BSC group (1:0.7). Primary sites were the lower gingiva in the BSC and the tongue in the non-BSC group. The BSC group exhibited higher NLR (p=0.50) and a significantly lower albumin level (p<0.001). Stage classification (I/II vs. III/IV) and ECOG-PS (0-1 vs. 2-4) differed significantly between groups (p<0.001). Cardiovascular disease was the most frequent comorbidity in both groups. Living situation exhibited no significant differences (p=0.99). The cumulative one-year OS rate in the BSC group was 29.8%, compared to 97.2% and 81.5% in the non-BSC group at one and five years, respectively. The cumulative one-year DSS rate in the BSC group was 31.9%, and 97.2% and 82.8% at one and five years in the non-BSC group were p<0.001 for OS and DSS. Age (OR: 1.20, 95% CI: 1.10-1.36; p=0.0008), stage classification (I/II vs. III/IV) (OR: 13.79, 95% CI: 2.34-137.75; p=0.0026), psychiatric disorder (OR: 8.73, 95% CI: 2.34-137.75; p=0.021), albumin level (OR: 0.03, 95% CI: 0.002-0.24; p=0.003) were factors in BSC. Among patients aged ≥75 years, stage classification (I/II vs. III/IV) (OR: 19.08, 95% CI: 2.51-321.07; p=0.0027), albumin level (OR: 0.003, 95% CI: 9.0×10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.